Actelion Ltd. | Income Statement

Fiscal year is January-December. All values CHF Millions.
2012
2013
2014
2015
2016
Sales/Revenue
1,728
1,786
1,958
2,045
2,418
Cost of Goods Sold (COGS) incl. D&A
236
255
278
265
333
Gross Income
1,493
1,531
1,680
1,780
2,085
SG&A Expense
1,070
1,036
1,110
1,124
1,296
EBIT
423
495
570
656
789
Unusual Expense
10
5
47
5
11
Non Operating Income/Expense
63
62
26
17
14
Interest Expense
13
12
14
11
-
Pretax Income
358
430
537
635
792
Income Tax
55
23
57
88
98
Consolidated Net Income
303
453
594
548
695
Net Income
303
453
594
552
696
Net Income After Extraordinaries
303
453
594
552
696
Net Income Available to Common
303
453
594
552
696
EPS (Basic)
2.61
4.06
5.34
5.09
6.66
Basic Shares Outstanding
116
112
111
108
105
EPS (Diluted)
2.57
3.92
5.11
4.91
6.46
Diluted Shares Outstanding
118
115
116
112
108
EBITDA
503
580
671
745
877
Non-Operating Interest Income
2
3
2
3
1
Minority Interest Expense
-
-
-
4
2

About Actelion

View Profile
Address
Gewerbestrasse 16
Allschwil Basel-Landschaft (Basle Country) 4123
Switzerland
Employees -
Website http://www.actelion.com
Updated 07/08/2019
Actelion Ltd. operates as a holding company with interests in developing, producing and marketing pharmaceutical drugs. It is a biopharmaceutical company, which focuses on the drug discovery, development, registration, production and commercialization of innovative drugs for diseases with significant unmet medical needs. Its portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications.